Catalog No.: PC-72055Not For Human Use, Lab Use Only.
Compound K (HPK1 inhibitor CompK) is a novel, potent, highly selective HPK1 (MAP4K1) kinase inhibitor with IC50 of 2.6 nM, 50-fold selectivity against other members of the MAP4K family.
HPK1 inhibitor CompK (HPK1-IN-7) is a novel, potent, highly selective HPK1 (MAP4K1) kinase inhibitor with IC50 of 2.6 nM, 50-fold selectivity against other members of the MAP4K family.
Compound K enhanced IFN-γ production in human CD8+ T cells with EC50 of 137 nM, showed potential benefit in restoring T-cell polyfunctionality under immunosuppressive conditions relevant to the TME.
CompK treatment demonstrated markedly enhanced human T-cell immune responses under immunosuppressive conditions relevant to the TME and an increased avidity of the T-cell receptor (TCR) to recognize viral and tumor-associated antigens (TAAs) in significant synergy with anti-PD1.
Animal model studies, revealed improved immune responses and superb antitumor efficacy in combination of CompK with anti-PD-1.
